Check out Michael Stumpp's presentation today at the Gordon Research Conferences and find out more about our first ²¹²Pb-labeled and DLL3-targeting RDT candidate, MP0712, for small cell lung cancer patients co-developed with Molecular Partners. #OranoMed #MolecularPartners #NuclearMedicine #MedicalInnovation #CancerResearch #Radiopharmaceuticals #Alphatherapy
This week Molecular Partners is at the Gordon Research Conferences Radionuclide Theranostics for the Management of Cancer to share insights about our #RadioDARPin Therapy (RDT) platform and our first RDT candidate, MP0712, targeting DLL3 in small cell lung cancer a 212Pb-labeled and DLL3-targeting RDT for small cell lung cancer patients in co-development with Orano Med. Join Michael Stumpp, EVP Projects, for his talk on July 10th at 9:00 AM ET and Alessandra Villa, Director Lead Generation, for her poster on July 11th at 4:00 PM ET to learn about our progress. View the full conference agenda here: https://bit.ly/3zaIPpB